Levodopa and Carbidopa

Brand names: Carbidopa And Levodopa · Active ingredient: Carbidopa, Levodopa

In short: Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

LabelAccord Healthcare, Inc.
Label updatedNov 09, 2026

What is Levodopa and Carbidopa used for?

Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

âš  Boxed warning (FDA's strongest warning)

When patients are receiving levodopa without a decarboxylase inhibitor, levodopa must be discontinued at least twelve hours before carbidopa and levodopa extended-release is started. In order to reduce adverse reactions, it is necessary to individualize therapy. see

DOSAGE AND ADMINISTRATIONsection before initiating therapy.

Carbidopa and levodopa extended-release should be substituted at a dosage that will provide approximately 25% of the previous levodopa dosage (

see

DOSAGE AND ADMINISTRATION

.)

Carbidopa does not decrease adverse reactions due to central effects of levodopa. By permitting more levodopa to reach the brain, particularly when nausea and vomiting is not a dose-limiting factor, certain adverse central nervous system (CNS) effects, e.g., dyskinesias, will occur at lower dosages and sooner during therapy with carbidopa and levodopa extended-release than with levodopa alone.

Patients receiving carbidopa and levodopa extended-release may develop increased dyskinesias compared to carbidopa and levodopa. Dyskinesias are a common side effect of carbidopa levodopa treatment. The occurrence of dyskinesias may require dosage reduction.

All patients should be observed carefully for the development of depression with concomitant suicidal tendencies.

Carbidopa and levodopa extended-release should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease. …

Levodopa and Carbidopa dosage

Carbidopa and levodopa extended-release tablets contain carbidopa and levodopa in a 1:4 ratio as either the 50 mg/200 mg tablet or the 25 mg/100 mg tablet. The daily dosage of carbidopa and levodopa extended-release must be determined by careful titration. Patients should be monitored closely during the dose adjustment period, particularly with regard to appearance or worsening of involuntary movements, dyskinesias or nausea. Carbidopa and levodopa extended-release tablets should not be chewed or crushed.

Standard drugs for Parkinson's disease, other than levodopa without a decarboxylase inhibitor, may be used concomitantly while carbidopa and levodopa extended-release is being administered, although their dosage may have to be adjusted.

Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, carbidopa and levodopa extended-release can be given to patients receiving supplemental pyridoxine (vitamin B

6).

Patients currently treated with conventional carbidopa levodopa preparations:Studies show that peripheral dopa-decarboxylase is saturated by the bioavailable carbidopa at doses of 70 mg a day and greater. Because the bioavailabilities of carbidopa and levodopa in carbidopa and levodopa and carbidopa and levodopa extended-release are different, appropriate adjustments should be made, as shown in

Table 2.

Tablet | Amount of

Levodopa (mg)

in Each Tablet | Approximate

Bioavailability | Approximate Amount

of Bioavailable

Levodopa (mg) in

Each Tablet

Carbidopa and Levodopa Extended-release

50 mg/200 mg | 200 | 0.70 to 0.75

The extent of availability of levodopa from carbidopa and levodopa extended-release tablets was about 70 to 75% relative to intravenous levodopa or standard carbidopa and levodopa tablets in the elderly. | 140 to 150

Carbidopa and Levodopa 25 mg/100 mg | 100 | 0.99

The extent of availability of levodopa from carbidopa and levodopa was 99% relative to intravenous levodopa in the healthy elderly. | 99

Dosage with carbidopa and levodopa extended-release should be substituted at an amount that provides approximately 10% more levodopa per day, although this may need to be increased to a dosage that provides up to 30% more levodopa per day depending on clinical response . The interval between doses of carbidopa and levodopa extended-release should be 4 to 8 hours during the waking day.

A guideline for

initiationof carbidopa and levodopa extended-release is shown in Table 3.

*For dosing ranges not shown in the table see

DOSAGE AND ADMINISTRATION, Initial Dosage —

Patients currently treated with conventional carbidopa levodopa preparations.

Carbidopa and Levodopa

Total Daily Dose*

Levodopa (mg) | Carbidopa and Levodopa Extended-Release

Suggested

Dosage Regimen

300 to 400 | 200 mg b.i.d.

500 to 600 | 300 mg b.i.d. …

Warnings & precautions

Do not take this medicine if: Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with carbidopa and levodopa extended-release. These inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. Carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCl) .

Carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

As with levodopa, periodic evaluations of hepatic, hematopoietic, cardiovascular, and renal function are recommended during extended therapy.

Dyskinesia

Levodopa alone, as well as carbidopa and levodopa extended-release, is associated with dyskinesias. The occurrence of dyskinesias may require dosage reduction.

Hallucinations / Psychotic-Like Behavior

Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In general, hallucinations present shortly after the initiation of therapy and may be responsive to dose reduction in levodopa. Hallucinations may be accompanied by confusion and to a lesser extent sleep disorder (insomnia) and excessive dreaming.

Carbidopa and levodopa extended-release may have similar effects on thinking and behavior. This abnormal thinking and behavior may present with one or more symptoms, including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium.

Ordinarily, patients with a major psychotic disorder should not be treated with carbidopa and levodopa extended-release, because of the risk of exacerbating psychosis. …

Levodopa and Carbidopa side effects

In controlled clinical trials, patients predominantly with moderate to severe motor fluctuations while on carbidopa and levodopa were randomized to therapy with either carbidopa and levodopa or carbidopa and levodopa extended-release. The adverse experience frequency profile of carbidopa and levodopa extended-release did not differ substantially from that of carbidopa and levodopa, as shown in

Table 1.

Adverse Experience | Carbidopa and

Levodopa

Extended-release

n = 491

% | Carbidopa and

Levodopa

n = 524

%

Dyskinesia | 16.5 | 12.2

Nausea | 5.5 | 5.7

Hallucinations | 3.9 | 3.2

Confusion | 3.7 | 2.3

Dizziness | 2.9 | 2.3

Depression | 2.2 | 1.3

Urinary tract infection | 2.2 | 2.3

Headache | 2.0 | 1.9

Dream abnormalities | 1.8 | 0.8

Dystonia | 1.8 | 0.8

Vomiting | 1.8 | 1.9

Upper respiratory infection | 1.8 | 1.0

Dyspnea | 1.6 | 0.4

‘On-Off’ phenomena | 1.6 | 1.1

Back pain | 1.6 | 0.6

Dry mouth | 1.4 | 1.1

Anorexia | 1.2 | 1.1

Diarrhea | 1.2 | 0.6

Insomnia | 1.2 | 1.0

Orthostatic hypotension | 1.0 | 1.1

Shoulder pain | 1.0 | 0.6

Chest pain | 1.0 | 0.8

Muscle cramps | 0.8 | 1.0

Paresthesia | 0.8 | 1.1

Urinary frequency | 0.8 | 1.1

Dyspepsia | 0.6 | 1.1

Constipation | 0.2 | 1.5

Abnormal laboratory findings occurring at a frequency of 1% or greater in approximately 443 patients who received carbidopa and levodopa extended-release and 475 who received carbidopa and levodopa during controlled clinical trials included: decreased hemoglobin and hematocrit; elevated serum glucose; white …

About this medicine

Carbidopa and levodopa extended-release tablets USP are for the treatment of Parkinson's disease and syndrome.

Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (—)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C

10H

14N

2O

4•H

2O and its structural formula is:

Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.3.

Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (—)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C

9H

11NO

4and its structural formula is:

Each extended-release tablet, for oral administration, contains either 50 mg of carbidopa USP and 200 mg of levodopa USP, or 25 mg of carbidopa USP and 100 mg of levodopa USP. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5217a6ec-cc26-4acc-b2da-17f6545c3b60. Read the full official label on DailyMed.